FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313263729> ?p ?o ?g. }

• W4313263729 endingPage "e37144" @default.
• W4313263729 startingPage "e37144" @default.
• W4313263729 abstract "Background Approximately 62% of patients with breast cancer with a pathogenic variant (BRCA1 or BRCA2) undergo primary breast-conserving therapy. Objective The study aims to develop a personalized risk management decision support tool for carriers of a pathogenic variant (BRCA1 or BRCA2) who underwent breast-conserving therapy for unilateral early-stage breast cancer. Methods We developed a Bayesian network model of a hypothetical cohort of carriers of BRCA1 or BRCA2 diagnosed with stage I/II unilateral breast cancer and treated with breast-conserving treatment who underwent subsequent second primary cancer risk–reducing strategies. Using event dependencies structured according to expert knowledge and conditional probabilities obtained from published evidence, we predicted the 40-year overall survival rate of different risk-reducing strategies for 144 cohorts of women defined by the type of pathogenic variants (BRCA1 or BRCA2), age at primary breast cancer diagnosis, breast cancer subtype, stage of primary breast cancer, and presence or absence of adjuvant chemotherapy. Results Absence of adjuvant chemotherapy was the most powerful factor that was linked to a dramatic decline in survival. There was a negligible decline in the mortality in patients with triple-negative breast cancer, who received no chemotherapy and underwent any secondary risk–reducing strategy, compared with surveillance. The potential survival benefit from any risk-reducing strategy was more modest in patients with triple-negative breast cancer who received chemotherapy compared with patients with luminal breast cancer. However, most patients with triple-negative breast cancer in stage I benefited from bilateral risk-reducing mastectomy and risk-reducing salpingo-oophorectomy or just risk-reducing salpingo-oophorectomy. Most patients with luminal stage I/II unilateral breast cancer benefited from bilateral risk-reducing mastectomy and risk-reducing salpingo-oophorectomy. The impact of risk-reducing salpingo-oophorectomy in patients with luminal breast cancer in stage I/II increased with age. Most older patients with the BRCA1 and BRCA2 pathogenic variants in exons 12-24/25 with luminal breast cancer may gain a similar survival benefit from other risk-reducing strategies or surveillance. Conclusions Our study showed that it is mandatory to consider the complex interplay between the types of BRCA1 and BRCA2 pathogenic variants, age at primary breast cancer diagnosis, breast cancer subtype and stage, and received systemic treatment. As no prospective study results are available at the moment, our simulation model, which will integrate a decision support system in the near future, could facilitate the conversation between the health care provider and patient and help to weigh all the options for risk-reducing strategies leading to a more balanced decision." @default.
• W4313263729 created "2023-01-06" @default.
• W4313263729 creator A5013239155 @default.
• W4313263729 creator A5016747318 @default.
• W4313263729 creator A5025554206 @default.
• W4313263729 creator A5036623254 @default.
• W4313263729 creator A5045522817 @default.
• W4313263729 creator A5055875311 @default.
• W4313263729 creator A5070917736 @default.
• W4313263729 creator A5077152126 @default.
• W4313263729 creator A5081470207 @default.
• W4313263729 date "2022-12-29" @default.
• W4313263729 modified "2023-10-17" @default.
• W4313263729 title "Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study" @default.
• W4313263729 cites W1605263017 @default.
• W4313263729 cites W1820854111 @default.
• W4313263729 cites W1945350395 @default.
• W4313263729 cites W1950977317 @default.
• W4313263729 cites W1968585700 @default.
• W4313263729 cites W1973683234 @default.
• W4313263729 cites W1974166138 @default.
• W4313263729 cites W1988843555 @default.
• W4313263729 cites W1990082384 @default.
• W4313263729 cites W1992211028 @default.
• W4313263729 cites W1995777454 @default.
• W4313263729 cites W2001864052 @default.
• W4313263729 cites W2002561481 @default.
• W4313263729 cites W2008233728 @default.
• W4313263729 cites W2009199535 @default.
• W4313263729 cites W2013038349 @default.
• W4313263729 cites W2029480573 @default.
• W4313263729 cites W2039211343 @default.
• W4313263729 cites W2044702943 @default.
• W4313263729 cites W2046536401 @default.
• W4313263729 cites W2058002784 @default.
• W4313263729 cites W2059064246 @default.
• W4313263729 cites W2062367399 @default.
• W4313263729 cites W2065151790 @default.
• W4313263729 cites W2068407303 @default.
• W4313263729 cites W2068652369 @default.
• W4313263729 cites W2069670984 @default.
• W4313263729 cites W2073129224 @default.
• W4313263729 cites W2079725471 @default.
• W4313263729 cites W2082125715 @default.
• W4313263729 cites W2087979878 @default.
• W4313263729 cites W2100860810 @default.
• W4313263729 cites W2104524178 @default.
• W4313263729 cites W2104976224 @default.
• W4313263729 cites W2105336986 @default.
• W4313263729 cites W2105455398 @default.
• W4313263729 cites W2107243201 @default.
• W4313263729 cites W2107878160 @default.
• W4313263729 cites W2108565008 @default.
• W4313263729 cites W2109772731 @default.
• W4313263729 cites W2114153887 @default.
• W4313263729 cites W2116234966 @default.
• W4313263729 cites W2118435622 @default.
• W4313263729 cites W2118728607 @default.
• W4313263729 cites W2123725304 @default.
• W4313263729 cites W2124189233 @default.
• W4313263729 cites W2127644335 @default.
• W4313263729 cites W2128088446 @default.
• W4313263729 cites W2129390137 @default.
• W4313263729 cites W2132266605 @default.
• W4313263729 cites W2133722660 @default.
• W4313263729 cites W2139269097 @default.
• W4313263729 cites W2142230152 @default.
• W4313263729 cites W2142491513 @default.
• W4313263729 cites W2143924924 @default.
• W4313263729 cites W2145703637 @default.
• W4313263729 cites W2147058464 @default.
• W4313263729 cites W2149994587 @default.
• W4313263729 cites W2157086121 @default.
• W4313263729 cites W2160335712 @default.
• W4313263729 cites W2162453996 @default.
• W4313263729 cites W2170136377 @default.
• W4313263729 cites W2170961135 @default.
• W4313263729 cites W2461958762 @default.
• W4313263729 cites W2519619548 @default.
• W4313263729 cites W2581871033 @default.
• W4313263729 cites W2627871710 @default.
• W4313263729 cites W2782723462 @default.
• W4313263729 cites W2792761659 @default.
• W4313263729 cites W2803428420 @default.
• W4313263729 cites W2905037142 @default.
• W4313263729 cites W2914478693 @default.
• W4313263729 cites W2917837889 @default.
• W4313263729 cites W3127992047 @default.
• W4313263729 cites W3155015744 @default.
• W4313263729 cites W4256127173 @default.
• W4313263729 cites W4376453948 @default.
• W4313263729 doi "https://doi.org/10.2196/37144" @default.
• W4313263729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36580360" @default.
• W4313263729 hasPublicationYear "2022" @default.
• W4313263729 type Work @default.
• W4313263729 citedByCount "2" @default.
• W4313263729 countsByYear W43132637292023 @default.
• W4313263729 crossrefType "journal-article" @default.

• next